Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Operations: 2009-2025

Historic Cash from Operations for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -$13.9 million.

  • Northwest Biotherapeutics' Cash from Operations fell 68.75% to -$13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.2 million, marking a year-over-year increase of 6.72%. This contributed to the annual value of -$57.0 million for FY2024, which is 6.30% down from last year.
  • Northwest Biotherapeutics' Cash from Operations amounted to -$13.9 million in Q3 2025, which was down 107.73% from -$6.7 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Cash from Operations registered a high of -$6.7 million during Q2 2025, and its lowest value of -$20.2 million during Q4 2024.
  • For the 3-year period, Northwest Biotherapeutics' Cash from Operations averaged around -$12.8 million, with its median value being -$12.4 million (2024).
  • In the last 5 years, Northwest Biotherapeutics' Cash from Operations slumped by 129.83% in 2022 and then skyrocketed by 58.71% in 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Cash from Operations (Quarterly) stood at -$11.2 million in 2021, then grew by 21.31% to -$8.8 million in 2022, then plummeted by 91.64% to -$17.0 million in 2023, then fell by 19.01% to -$20.2 million in 2024, then crashed by 68.75% to -$13.9 million in 2025.
  • Its last three reported values are -$13.9 million in Q3 2025, -$6.7 million for Q2 2025, and -$9.4 million during Q1 2025.